TY - JOUR
T1 - Beat-to-beat variability of T-wave amplitude for the risk assessment of ventricular tachyarrhythmia in patients without structural heart disease
AU - Sobue, Yoshihiro
AU - Watanabe, Eiichi
AU - Yamamoto, Mayumi
AU - Sano, Kan
AU - Harigaya, Hiroto
AU - Okuda, Kentarou
AU - Ozaki, Yukio
PY - 2011/11
Y1 - 2011/11
N2 - Aims Increased temporal repolarization lability, assessed by beat-to-beat variability of T-wave amplitude (TAV), has been shown to be associated with ventricular tachyarrhythmia in patients with a variety of clinical conditions. The aim of this study was to test the ability of TAV to identify patients presenting with malignant ventricular arrhythmia and to predict subsequent occurrences. Methods and results We studied 20 consecutive patients (age 42 ± 15 years, mean ± standard deviation) presenting with ventricular tachyarrhythmia who did not have substantial underlying heart disease and compared them with 40 age- and sex-matched control subjects. The TAV was determined by Holter recording (Ela Medical). Patients with ventricular tachyarrhythmia had a higher maximum value of TAV (max TAV: 38 ± 18 vs. 22 ± 15 μV, P< 0.001) than did the controls. The sensitivity and specificity of max TAV>22.4 μV for detecting the occurrence of ventricular tachyarrhythmia were 77 and 90%, respectively. During a mean follow-up period of 23 months, three patients had relapses of ventricular tachyarrhythmia. Patients with a recurrence of ventricular tachyarrhythmia had a trend towards a higher max TAV as compared with those who had ventricular tachyarrhythmia but did not relapse (56 ± 23 vs. 36 ± 16 μV, P = 0.061). Conclusion Our results suggest that Holter-derived TAV might be associated with the occurrence and recurrence of ventricular tachyarrhythmia in patients without structural heart disease. Prospective validation will be necessary to assess the potential diagnostic value of the TAV in a large general population.
AB - Aims Increased temporal repolarization lability, assessed by beat-to-beat variability of T-wave amplitude (TAV), has been shown to be associated with ventricular tachyarrhythmia in patients with a variety of clinical conditions. The aim of this study was to test the ability of TAV to identify patients presenting with malignant ventricular arrhythmia and to predict subsequent occurrences. Methods and results We studied 20 consecutive patients (age 42 ± 15 years, mean ± standard deviation) presenting with ventricular tachyarrhythmia who did not have substantial underlying heart disease and compared them with 40 age- and sex-matched control subjects. The TAV was determined by Holter recording (Ela Medical). Patients with ventricular tachyarrhythmia had a higher maximum value of TAV (max TAV: 38 ± 18 vs. 22 ± 15 μV, P< 0.001) than did the controls. The sensitivity and specificity of max TAV>22.4 μV for detecting the occurrence of ventricular tachyarrhythmia were 77 and 90%, respectively. During a mean follow-up period of 23 months, three patients had relapses of ventricular tachyarrhythmia. Patients with a recurrence of ventricular tachyarrhythmia had a trend towards a higher max TAV as compared with those who had ventricular tachyarrhythmia but did not relapse (56 ± 23 vs. 36 ± 16 μV, P = 0.061). Conclusion Our results suggest that Holter-derived TAV might be associated with the occurrence and recurrence of ventricular tachyarrhythmia in patients without structural heart disease. Prospective validation will be necessary to assess the potential diagnostic value of the TAV in a large general population.
UR - http://www.scopus.com/inward/record.url?scp=80054891313&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054891313&partnerID=8YFLogxK
U2 - 10.1093/europace/eur177
DO - 10.1093/europace/eur177
M3 - Article
C2 - 21712269
AN - SCOPUS:80054891313
SN - 1099-5129
VL - 13
SP - 1612
EP - 1618
JO - Europace
JF - Europace
IS - 11
ER -